Physician profile
Ina A Lim
NPI 1073891768
$4,485.35
in general payments reported to CMS, 2019-2025
31 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $824 · 2021: $241 · 2022: $803 · 2023: $618 · 2024: $924 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,617.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $822.97 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $819.57 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $663.61 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $428.52 | 2020-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.21 | 2020-2025 | Jardiance |
| Pfizer INC. | $231.75 | 2020-2025 | |
| Inspire Medical Systems, INC. | $163.66 | 2022-2024 | Inspire |
| Glaxosmithkline, LLC. | $147.65 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $124.12 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $117.77 | 2020-2022 | |
| Abbott Laboratories | $105.04 | 2022-2023 | Freestyle Libre 3 |
| Abbvie INC. | $92.34 | 2024-2025 | |
| Shield Therapeutics INC | $63.32 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $56.24 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Seqirus USA INC | $48.15 | 2024-2025 | Flucelvax, Fluad |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $39.66 | 2020 | |
| Amarin Pharma, INC. | $38.81 | 2020-2021 | |
| Astellas Pharma US INC | $32.98 | 2023 | Veozah |
| Vanda Pharmaceuticals INC. | $26.24 | 2023 | Fanapt, Hetlioz |
| Alnylam Pharmaceuticals INC. | $22.44 | 2022 | |
| Esperion Therapeutics, INC. | $22.03 | 2025 | Nexletol |
| Gilead Sciences, INC. | $21.62 | 2024 | |
| Janssen Pharmaceuticals, INC | $20.58 | 2020 | |
| Phadia US INC. | $19.97 | 2020 | |
| Medtronic, INC. | $19.18 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.51 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.61 | 2020 | |
| Horizon Therapeutics Plc | $17.10 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.72 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.66 | 2022 | |
| Allergan, INC. | $16.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ina Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.